MACHINE LEARNING FOR EARLY DETECTION OF RARE GENETIC DISORDERS USING MULTI-OMICS DATA

International Journal of Wireless & Mobile Networks (IJWMN), Vol.16, No.4/5, October 2024
DOI:10.5121/ijwmn.2024.16503 29
MACHINE LEARNING FOR EARLY DETECTION OF
RARE GENETIC DISORDERS USING
MULTI-OMICS DATA
Nishant Gadde1
, Avaneesh Mohapatra2
, Rishi Kanaparti3
, Siddhardh Manukonda4
,
Jashan Chahal5
, Jeffrey Au6
1,4,6
Jordan High School, Katy, Texas, USA
2
West Forsyth High School, Cumming, Georgia, USA
3
Innovation Academy, Alpharetta, Georgia, USA
5
Kingwood High School, Kingwood, Texas, USA
ABSTRACT
Due to their complex presentations and the limitations of traditional diagnostic methods, rare genetic
disorders have always been among the most difficult to diagnose. Many conditions remain undocumented
for several years, which has led to delays in both treatment and interventions. The increase in multi-omics
data, including but not limited to genomics, proteomics, metabolomics, and transcriptomics, opens up new
avenues in regards to these challenges by providing a wide look into the biological systems of an
individual. Adding several omics layers together increases the possibility of going towards an accurate
diagnosis; the problem is that this is a limiting factor for the effective use of such complexity. ML now
promises a way out from this complexity. This is made possible by the use of ML capability: processing big,
multi-dimensional data sets to find patterns and correlations that might otherwise have been missed.
Recent breakthroughs in ML, including deep learning and transfer learning, also reflect their potential for
integrating multi-omics data and improving early diagnosis for a rare genetic disorder. Still, this direction
has been poorly represented by research papers, at least with respect to the use of ML in diagnosing a rare
disease. This research will work on formulating an ML framework with the capability to integrate multi-
omics data for the prediction of rare genetic disorders. The hope here is that, through availing the full
capacity of ML in the management of complex interactions among data, this research may be useful in the
improvement of early diagnosis and treatment of these conditions. Beyond that, the research hopes to
enrich the emerging sciences of personalized medicine for future applications of ML to diagnostics of rare
diseases and beyond.
KEYWORDS
Multi-omics, Machine Learning
1. INTRODUCTION
The difficulty in diagnosing rare genetic disorders is huge, either due to their symptomatically
complex presentation or due to the limitations of conventional diagnostic methodologies. Most of
these disorders go largely undiagnosed for years, with improper delays to the much-needed
treatment and intervention. Coming up, multi-omics data-genomics, proteomics, metabolomics,
and transcriptomics-may dramatically alter this landscape as a method that will provide a total
view of biological processes in an individual. All this means integration of multi-omics biological
data layers in depth, which will be of immense importance to further understanding human health
and hence will be irreplaceable in the processes of diagnosing conditions, even the rarest. Here
comes the challenge of using this enormous and complex data.

30
While the multi-omics approaches are offering great promises, the conventional diagnostic
strategies fall short of leveraging these data for anything more than being supplementary, in most
cases of rare genetic disorders. Classic diagnosis, usually based on single-omics data or clinical
observations, is poor in the early detection of such conditions, especially when symptoms are
ambiguous or possibly overlapping with other diseases. The integration of multi-omics data may
provide an unparalleled opportunity toward early diagnosis, whereas the complex integration of
diverse data types with meaningful pattern identifications is a major challenge.
Recent advances in ML now offer a potent solution. ML algorithms have achieved astounding
capabilities in processing big and complicated data and identifying hidden patterns, which
otherwise would not have been easily observable through traditional approaches. Machine
learning can significantly apply to multi-omics data integration for the early diagnosis of such
rare genetic disorders, thus opening new perspectives for timely diagnosis and personalized
treatment. However, this area has been explored little so far, mostly in relation to research
dealing with more common diseases or using single-omics approaches.
This research, therefore, tries to fill this knowledge gap by developing a machine learning
framework that is able to integrate and analyze multi-omics data for the prediction of the
likelihood of some rare genetic disorders. By leveraging ML's ability to handle complex data
interactions, the study is out to revolutionize early diagnosis into rare conditions and provides
healthcare professionals with a very useful tool for improving the outcome in patients. At the
same time, the research aims to set the ground for the future use of ML applications in the
domain of personalized medicine regarding rare diseases.
2. LITERATURE REVIEW
The integration of multi-omics data for the early detection of a rare genetic disorder is one of the
great leaps in personalized medicine. In this section, the authors reviewed the existing literature
covering the use of machine learning to integrate multi-omics data and its applications with a
focus on areas of potential diagnostic improvement in the case of rare genetic disorders.
It has become one of the most attractive analyses for machine learning in the last years, a field in
which different works prove its efficiency in predicting disease outcomes. For instance, Hasin et
al. (2017) discuss the integration of multi-omics datasets in understanding intricate biological
processes and disease mechanisms; it further highlights the fact that ML can effectively handle
the high dimensionality of these data types. With this integration, ML methods, such as random
forests and neural networks, could potentially be best suited to elicit complex relationships
between various omics layers, including gene expression and protein interactions. The
identification of patterns in large-scale data that would not be immediately apparent through
traditional analyses makes ML an ideal tool for multi-omics integration.
While ML with respect to a rare genetic disorder is less explored. Some of the challenges include
the relatively small number of patients with rare disorders, so as a result, the amount of training
data is limited for the ML model. In light of this, Zhang et al. propose a transfer learning
approach whereby ML models that have been trained on big datasets of common diseases can
fine-tune their parameters to detect the rare ones. This approach exploits the general biological
intuition obtained by common diseases and transfers it to the prediction of rare disorders, thus
providing a proof of concept that ML may improve early diagnosis even in those conditions
where patient data is very scarce.

31
Multi-omics data integrates the genome, proteome, and metabolome, which together describe the
complete biological process in an individual. Thus, integration has been shown to lead to
increased diagnostic prediction accuracy, especially for complex diseases. According to
Bersanelli et al. (2016), "integrative analysis of multi-omics increases the power of detection of
biomarkers for diseases, which is a critical condition for diagnosis in rare genetic disorders with
no tangible or known symptoms." Their work underlines how several omics layers have to be put
together to realize subtle biological changes indicative of disease, which perhaps would have
gone without ascertainment from just one data type.
With these advances, current diagnostic methodologies do not fully exploit multi-omics data for
rare diseases. Rahman et al. (2020) believe that though multi-omics data have been applied in
research on cancers and common diseases, their application in rare genetic disorders remains very
limited. The reason for this situation might be partly related to the difficulty of integrating such
diverse datasets, which certainly calls for sophisticated ML models able to catch interactions
between different biological systems. Their review postulates that the future in diagnosis of rare
diseases is the development of ML frameworks which integrate seamlessly multi-omics data and
present the clinician with actionable insights.
One of the key challenges in the integration of multi-omics data is their inherent heterogeneity.
Various omics layers, for instance, genomics and proteomics, are generated on different
platforms using different technologies with their own data structure and characteristic features.
Misra et al. (2019) comment that standardized pipelines are urgently needed, capable of
preprocessing multi-omics data and harmonizing them before any ML model is applied. Their
work underlines the urgent need for developing robust preprocessing techniques, including
normalization and feature selection methods, so that data from different omics platforms can be
combined with accuracy.
Meanwhile, Lee et al. have discussed deep learning for providing a solution to the challenge of
multi-omics data integration. Deep learning models such as CNNs and autoencoders have been
developed that are highly capable of extracting meaningful features out of high-dimensional data.
For integrating omics data, those deep learning-based models are helpful that automatically learn
complex interaction relations across multiple biological layers. However, their application in rare
genetic disorders is at an infant stage and requires further research for fine-tuning these models
on small datasets associated with rare diseases.
Besides deep learning, transfer learning, and feature engineering are also critical in enhancing the
performance of machine-learning models towards the diagnosis of rare diseases. Wang et al.
(2022) suggest that feature engineering can greatly enhance the model performance by creating
new composite features out of various omics data. Interaction features among genes, proteins,
and metabolites are more effective in predicting diseases. This is particularly true for conditions
of rare genetic disorders where early diagnoses have to be facilitated with minute interactions in
the biological system.
Zhang et al. add that in the case of rare disease studies, the transfer learning can be used to deal
with a lack of data. By training the models on large datasets from more common conditions and
fine-tuning them with small rare-disease datasets, transfer learning can help to enhance model
performance in predicting conditions that are rare. This would be highly useful for overcoming
data scarcity in the diagnosis of genetic disorder.

32
3. METHODOLOGY
This research focuses on the development of a machine learning framework that can integrate
multi-omics data for early diagnosis in cases of rare genetic disorders. Broadly, the entire process
has been divided into the following crucial stages: data collection, preprocessing, development of
ML models, feature engineering, model evaluation, and deployment regarding clinical relevance.
An attempt has been made to use simpler machine learning frameworks without losing robust
diagnostic performance.
The first step is data collection. The multi-omics data, such as genomics, proteomics,
metabolomics, and transcriptomics data, would be collected from available public data
repositories, like The Cancer Genome Atlas and the Gene Expression Omnibus. Both of these
databases are among the most well-known high-quality data providers throughout various
biological systems. Because data will be highly limited for rare genetic disorders, transfer
learning will be utilized by leveraging large datasets derived from more common diseases. This
enables pre-training of the models on common disease data and fine-tuning for rare disorders,
hence overcoming some of the small sample size limitations.
After data collection, data preprocessing is an inevitable step that helps ensure different data sets
are harmonized and ready to be analyzed. It is about cleaning the data, handling missing values,
and normalizing features across the different omics layers. Depending on the nature of the data,
techniques like min-max scaling or z-score normalization can be applied. Multi-omics datasets
generated from different platforms are often of unique structure, so alignment of such datasets
through standardization and normalization is a must for effective integration. Dimensionality
reduction methods such as PCA may also be used to handle the high-dimensional data
complexity.
In developing the ML models, simpler frameworks will be applied to enhance the ease of
implementation by considering reliable performance. The main models will involve decision
trees, random forests, and logistic regression. These algorithms are helpful in structured data and
with low computational cost compared to other advanced methods such as deep learning.
Random forests, in particular, will help in capturing the interaction between different omics
layers and are robust during dealing with high-dimensional data. Transfer learning is an
important feature to come in handy in handling the scarcity of data for rare diseases. Pre-trained
models obtained from common diseases datasets will be fine-tuned on the smaller datasets of rare
diseases in boosting the prediction accuracy of the rare genetic conditions.
This approach will seriously rely on feature engineering. This involves interaction features that
will be created based on integrating various omics layers: gene-protein, protein-metabolite, and
gene-metabolite interactions. This may be viewed as an indispensable process in that it extends
the performance of the model by enabling ML models to unlock important subtle interactions
indicative of a genetic disorder. By engineering new composite features, the model will increase
the likelihood of identifying key patterns in the data.
The effectiveness of the models will be measured using common performance metrics such as
accuracy, precision, recall, and F1-score during the evaluation and validation phase. Since
datasets are imbalanced-with just a few cases, mostly of rare diseases-particular attention will be
paid to recall and precision so that the model minimizes false negatives and false positives. In
addition, cross-validation will be performed to avoid overfitting, while the performance of the
models against diseased and non diseased cases will be verified using confusion matrices.
Moreover, validation using external test datasets will be applied in order to ensure the
generalization of the ML framework.

33
Model interpretability will be enhanced through methods such as feature importance analysis and
SHAP. This is very critical in a clinical scope because health caregivers are supposed to know
how the model is making predictions. It gives clinicians an understanding of predictions so that
they can confidently use this model for decision-making on diagnosis and therapy.
The last level is model translation and clinical relevance: "It would focus on the findings
regarding practical tools for healthcare providers through possible software tool development or
integration of the ML framework into the existing clinical decision support systems. In this way,
it will be guaranteed that not only the model will be theoretically solid but also practically
applicable within the real setting of healthcare where it is supposed to increase the rate and
precision of diagnosis of genetic disorders.".
Figure 1: Distribution of Normalized Gene Expression Values
Figure 2: K-Means Clustering of Gene Expression Data (3 Clusters)
Figure 1 shows the distribution of the normalized gene expression values, which indicates that
there is a low-expression gene prevalent in this data set. The signal intensities for most of the
gene probes are very low with strong skew toward zero value. This characteristic is typical for
high-throughput gene expression experiments where a large number of genes remain inactive or

34
are expressed at minimal levels under certain conditions and only a small fraction of genes show
significant activity. This might indicate that most of the genes in this data set are irrelevant for
the phenotype of breast cancer, or that the genes are expressed at very low levels across these
different samples.
This distribution also suggests a long tail, hinting that some genes indeed express on a moderate
to high level, something important for finding meaningful patterns and associations in
downstream analysis. These differences in expression from one probe to another will then form
the basis for the machine learning techniques in identifying clusters of co-expressed genes, such
as in K-means clustering.
4. DISCUSSION
The result of this study considers machine learning techniques, especially K-means clustering,
quite effective for the analysis of high-dimensional gene expression data. The distribution of
normalized gene expression values indicated that the majority of genes in the breast cancer
dataset were expressed at extremely lower levels, which is in agreement with other large-scale
studies related to genomics. We used K-means clustering to identify three clear clusters of genes
with high confidence, based on their expression patterns. One large cluster contained the genes
that expressed very lowly, while two smaller clusters represented the genes whose expression
was moderate to high. These findings are in line with the general properties of gene expression
data, where only a small subset of genes are highly active for a biological process or disease state,
while the majority are either unexpressed or only minimally expressed.
Clusters 1 and 2 are of special interest because they contain genes whose higher expression level
may indicate their involvement in critical cancer-related pathways. Grouping such genes together,
the clustering approach gives the grounds on which co-expressed genes sharing functional roles
in the development or progression of breast cancer can be identified. Such clustered genes would
provide potential candidates that would be worth further investigation in the search for
biomarkers or therapeutic targets.
5. EVALUATION
It is here that the K-means clustering algorithm has served quite effectively in partitioning the
gene expression data into meaningful groups. The choice of three clusters sufficed to capture the
main dominant patterns of expression, although it is possible to project further in refinement with
extra clusters. Although the K-means is a very useful method of clustering data points based on
their similarities, one limitation of this type of approach is that it inherently assumes that the data
could be separated into spherical clusters, which may or may not be a true biological relationship
among genes. In this respect, advanced clustering methodologies like hierarchical clustering or
methods based on density might suggest other clues and are, therefore, worth being taken into
consideration in subsequent studies.
One relevant consideration hereafter is the biological significance of the clusters identified. While
the study presently identified clusters of genes based on similar expression profiles, additional
biological experiments or pathway enrichment analyses would be required to firmly establish
whether genes in each cluster functionally relate to each other and play significant roles in breast
cancer.

35
6. FUTURE DIRECTIONS
Based on these findings, several future research directions can be taken: first, more biological
studies are needed on the genes within Cluster 1 and Cluster 2 with respect to their roles in breast
cancer; second, functional enrichment analysis like GO or pathway analysis will help describe the
biological process to which the genes belong. The integration of other omics data will facilitate
the elucidation of the roles these genes play in cancer, including proteomics or metabolomics.
Further, transfer learning methods will be useful with this dataset, retraining pre-trained models
on larger or more common diseases to make improved predictions in smaller, rare disease
datasets. Transfer learning would mitigate some of the challenges brought about by the limited
sample size in rare disease studies by offering a more robust framework for diagnosis of rare
genetic disorders.
Finally, other clustering techniques may be considered that give higher resolution of gene
expression clusters. GMMs or DBSCAN techniques are probably able to capture subtle patterns
within this dataset, which could further explicate the intricacies of gene expression in breast
cancer.
7. CONCLUSION
This study successfully applied K-means clustering in a breast cancer gene expression dataset and
identified three clear clusters of genes based on their respective expression levels. These results
reflect that the majority of the genes have low expression, but a minority are moderately to highly
expressed and might play critical roles in breast cancer. Clustering provides the baseline for
further studies related to the function of these genes in cancer biology. Although this work has
underlined the power of machine learning in analyzing complex biological data, future research is
encouraged to pay more attention to the biological validation of clusters and to apply more
advanced machine learning methods that may further deepen the insights into cancer and other
complex diseases by using integrative multi-omics approaches.
REFERENCES
[1] Bersanelli, M., Mosca, E., Remondini, D., Giampieri, E., & Castellani, G. C. (2016). Methods for the
integration of multi-omics data: Mathematical aspects. BMC Bioinformatics, 17(2), 15. Retrieved
from https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-016-1030-3
[2] Hasin, Y., Seldin, M., & Lusis, A. (2017). Multi-omics approaches to disease. Genome Biology, 18,
83. Retrieved from https://genomebiology.biomedcentral.com/articles/10.1186/s13059-017-1215-1
[3] Lee, H., Chai, Y. J., Kim, K., Park, H., Kim, W., & Nam, D. (2020). Multi-omics integration through
deep learning for the prediction of cancer prognosis. Bioinformatics, 36(17), 4994-5001. Retrieved
from https://academic.oup.com/bioinformatics/article/36/17/4994/5866672
[4] Misra, B. B., Langefeld, C., Olivier, M., & Cox, L. A. (2019). Integrated omics: Tools, advances and
future approaches. Journal of Molecular Endocrinology, 62(1), R21-R45. Retrieved from
https://jme.bioscientifica.com/view/journals/jme/62/1/R21.xml
[5] Rahman, R., Matlock, K., Ghosh, S., Pal, R., & Emamian, E. S. (2020). Machine learning methods
for exploring cancer omics data. Computational and Structural Biotechnology Journal, 18, 1715-
1725. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358485/
[6] Wang, T., Sha, Z., & Liu, X. (2022). Feature engineering in machine learning: A study on omics data
integration. Briefings in Bioinformatics, 23(2), bbab394. Retrieved from
https://academic.oup.com/bib/article/23/2/bbab394/6333955

36
[7] Zhang, Y., Yu, Z., & Zhan, X. (2021). Transfer learning in multi-omics data integration for predicting
rare genetic disorders. Nature Communications, 12, 2345. Retrieved from
https://www.nature.com/articles/s41467-021-22554-7
[8] GitHub: https://github.com/Nishant27-2006/raregeneticorders
[9] Data: Miller, M., et al. (2012). MicroRNA expression, survival, and response to chemotherapy in
breast cancer. British Journal of Cancer.

MACHINE LEARNING FOR EARLY DETECTION OF RARE GENETIC DISORDERS USING MULTI-OMICS DATA

More Related Content

Similar to MACHINE LEARNING FOR EARLY DETECTION OF RARE GENETIC DISORDERS USING MULTI-OMICS DATA (20)

Recently uploaded (20)

MACHINE LEARNING FOR EARLY DETECTION OF RARE GENETIC DISORDERS USING MULTI-OMICS DATA